SniffPhone, an EU funded project to develop a compact handheld device that measures exhaled breath for early diagnosis of cancer, has received the Innovation Award at EFECS2018 - the European Forum for Electronic Components and Systems in Lisbon.

Award to project SNIFFPHONE for most Innovative project

The SNIFFPHONE project has been acknowledged by the European Commission as one of the most innovative H2020 projects in the area of "Electronic Components and Systems". The project received the Innovation Award on 21 November 2018 in Lisbon, in the context of the European Forum for Electronic Components and Systems - EFECS2018.

Supported under the European Union Horizon 2020 Programme for Research & Innovation, SNIFFPHONE developed a compact handheld device that measures exhaled breath for early diagnosis of cancer. It works by holding the device in front of the mouth, exhaling onto the device, taking a sample of the exhaled breath and measuring the contained Volatile Organic Compounds (VOCs). This is done by using highly sensitive nanotechnology-based chemical sensors, the measurements of which are sent wirelessly (Bluetooth of a smartphone) to a dedicated cloud platform and analyzed by specialist medical personnel.

The award, that highlights outstanding innovation amongst the projects that have received funding from the European Union Research & Innovation Horizon 2020 support programme, was received by Prof. Hossam Haick of the Technion Institute of Technology in Israel and Dr. Jan Mitrovics of JLM Innovation GmbH, as representatives of the SNIFFPHONE Consortium, who were delighted to be selected as winners of the Innovation Award, recognizing that the SNIFFPHONE device already presents an advantage over traditional screening methods.

The SNIFFPHONE consortium consists of nine partners from six countries, covering all aspects of the technology development and validation:

  • Nanosensors developed in Israel;
  • Micropump by Cellix in Ireland;
  • Fluidics by Microfluidic ChipShop in Germany;
  • Cloud platform by VTT in Finland;
  • Clinical studies by the University of Latvia in Riga;
  • Further testing and technical experimentation at the University of Innsbruck in Austria;
  • Siemens - part of the testing and validation phase;
  • System integration, device software and app by JLM Innovation in Germany.

“With this new method of diagnosis, SniffPhone has an unparalleled advantage over traditional screening methods: the device is comfortable and painless to use and provides a simple and cost-effective alternative for medical professionals.”

Smart Phone for Disease Detection from Exhaled Breath
Project coordinator
Project Acronym